Cancer Clinical Trials

(101-10) NCT01189851 Intraoperative Radiotherapy (IORT) for the Management of Carcinoma of the Breast: Use of Mammography, Ultrasonography and Contrast-Enhanced Magnetic


(102-15) Data Registry for Early Stage Breast Cancer: Prospective Data Collection and Analyses of Wide Local Excisions and Intraoperative Radiotherapy


(131-17) 0C-16-8: A Phase ½ Safety Study of Intratumorally Administered INT230-6 in Adult Subjects with Advanced Refractory Cancers (Phase 1 clinical trial appropriate for patients with solid tumors)


(152-17) OC-14-9: A Modular Phase I, Open-Label, Multicenter Study to Assess Ascending Doses of AZD6738 in Combination with Chemotherapy and/or Novel Anti Cancer Agents (Phase 1 clinical trial appropriate for patients with advanced solid malignancies of the breast)


(155-17) 0C 17-1: Phase I Multicenter Study of the Safety of Pharmacokinetics and Preliminary Efficacy of CBT-101 in Subjects with Advanced Solid Tumors and C-Met Dysregulation (Phase 1 clinical trial appropriate for patients with advanced solid malignancies)


(187-17) 0C-17-11: Phase 1 trial of ZW25 in patients with locally advanced (unresectable) and/or metastatic HER2-expressing cancers (Phase 1 clinical trial, appropriate for patients with HER2 expressing cancers.)


(211-17) 0C-17-14: An Open-Label, Non-Randomized, Multicenter Study to Determine the Pharmacokinetics and Safety of Niraparib Following a Single Oral Dose in Patients with Advanced Solid Tumors and Either Normal Hepatic Function or Moderate Hepatic Impairment (Phase 1 Clinical trial appropriate for patients with advanced solid tumors)


(214-17) OC-17-17: A Phase 1/2 First-in-human Study of BMS-986258 Alone and in Combination with Nivolumab in Advanced Malignant Tumors (Phase 1/2 clinical trial, appropriate for patients with advanced malignant tumors.)


181-17/0C-14-2: An Open-Label, Phase 2 study of Neratinib in Patients with Solid Tumors with Somatic Human Epidermal Growth Factor Receptor (EGFR, HER2, HER3) Mutations or EGFR Gene Amplification


157-17/0C-18-2: A Phase I Study of FID-007 in Patients with Advanced Solid Tumors


114-17: A Randomized Phase II/Phase III Study Of Adjuvant Concurrent Radiation And Chemotherapy Versus Radiation Alone In Resected High-Risk Malignant Salivary Gland Tumors


112-16: NSABP PROTOCOL B-51/RTOG PROTOCOL 1304 - A Randomized Phase III Clinical Trial Evaluating Post-Mastectomy Chest wall and Regional Nodal XRT and Post-Lumpectomy Regional Nodal XRT in Patients with Positive Axillary Nodes Before Neoadjuvant Chemotherapy Who Convert to Pathologically Negative Axillary Nodes After Neoadjuvant Chemotherapy


(107-18) 0C-17-5: A Phase 1b/2 Study of BMS-813160 in Combination with Chemotherapy or Nivolumab in Patients with Advanced Solid Tumors (Phase 1b/2 clinical trial, appropriate for patients with colorectal or pancreatic cancer)


(133-17) 3C-16-5: A Multicenter, Randomized, Open-label, 3-Arm Phase 3 Study of Encorafenib + Cetuximab Plus or Minus Binimetinib vs. Irinotecan/Cetuximab or Infusional 5-Fluorouracil (5-FU)/Folinic Acid (FA) /Irinotecan (FOLFIRI)/Cetuximab with a Safety Lead-in of Encorafenib + Binimetinib+ Cetuximab in Patients with BRAF V600E-mutant Metastatic Colorectal Cancer (Phase 3 clinical trial, appropriate for patients with colorectal cancer.)


(175-17) A randomized phase II study comparing selumetinib to placebo for enhancing the clinical efficacy of radioactive iodine (RAI) for recurrent/metastatic thyroid cancers that retain RAI uptake. Principal Investigator: Michael J. Demeure, M.D., F.A.C.S., F.A.C.E. Sub-Principal Investigator: George B. Semeniuk, M.D.


(144-17) 0S-16-18:A Phase Ib Study of Guadecitabine (SGI-110) and Durvalumab (MEDI 4736) in Patients with Advanced Hepatocellular Carcinoma, Pancreatic Adenocarcinoma, and Cholangiocarcinoma/Gallbladder Cancer (0S-16-18: PIb (SGI-110) and (MEDI 4736))(Phase 1b clinical trial, appropriate for patients with advanced liver, pancreatic, bile duct, or gallbladder cancer.)


119-17: Noncoding RNA Biomarkers for Noninvasive and Early Detection of Pancreatic Cancer


(149-17) Phase II, Double-Blind, Randomized Trial of AVOVA-1 (Autologous Dendritic Cells Loaded with Autologous Tumor Associated Antigens) vs. Autologous Peripheral Blood Mononuclear Cells (MC) in Patients with Stage II or IV Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma after Primary Therapy (Phase II clinical trial, appropriate for patients with ovarian cancer)


(106-16) 0S-15-5: A Pilot Multi-Arm Study of sEphB4-HSA in Combination with Different Chemotherapy Regimens in Patients with Specific Advanced or Metastatic Solid Tumors


(134-17) 0S-16-8:Phase IIa trial of sEphB4-HSA in combination with Anti PD-1 Antibody (Pembrolizumab, MK-3475) in patients with non-small cell lung and head and neck cancer


(132-17) 3L-16-4 A Phase Ib/II Clinical Study of BBI608 in Combination with Sorafenib or BBI503 in Combination with Sorafenib in Adult Patients with Hepatocellular Carcinoma(Phase 1 clinical trial, appropriate for patients with liver cancer.)


151-17/0C-14-11: A Phase 1, Open-Label, Dose Escalation Study Of Pf-04518600 As A Single Agent And In Combination With Pf-05082566 In Patients With Selected Locally Advanced Or Metastatic Cancers


(109-17) 2N-16-3: A Phase 2, Fast Real Time Assessment of Combination Therapies in Immuno-Oncology Stud in Subjects with Advanced Non-small Cell Lung Cancer (FRACTION-Lung)


(104-17) DecisionDx-Melanoma 31-Gene Expression Profile Clinical Impact Study #4. PI: Binh Ngo, M.D.


135- 17 Caris Molecular Intelligence® and Caris Centers of Excellence for Precision Medicine NetworkTM Outcomes Associated Repository


136- 17 Caris Molecular Intelligence® and Caris Centers of Excellence for Precision Medicine Retrospective Outcomes-Associated Database


167-17 Caris ctDNA Validation Project


179-17 Pharmacogenetics Program Pilot program to assess the potential role of pharmacogenomics to improve drug safety in patients with advanced cancer.


204-17 Advance Treatment of Rare Tumors (tumor and normal tissue collection for gene expression array, CGH, NGS, and blood for NGS testing)


101-18: Registry of patients in kindreds with germ-line TP53 mutations (Li-Fraumeni)


(208-17) 0C-17-15: A multicenter, open-label, phase 1b/2 study to evaluate safety and efficacy of avelumab (MSB0010718C) in combination with chemotherapy with or without other anti-cancer immunotherapies as first-line treatment in patients with advanced malignancies (Phase 1b/2 clinical trial, appropriate for patients with bladder and lung cancers.)


(117-16) Prostate Cancer Active Surveillance: Data Registry for Active Surveillance Management of Prostate Cancer: Prospective Data Collection and Analysis


115-16: Stereotactic Body Radiation Therapy (Sbrt) For The Management Of Carcinoma Of The Prostate: Quality Of Life Data After Primary Stereotactic Body Radiation Therapy For Localized Prostate Cancer


113-16: Data Registry for Pancreatic Cancer Early Detection: Prospective Data Collection and Analysis

Click here for a complete, up-to-date list of Cancer Clinical Trials.

For more information call: 949-722-6237